Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.

Popular Topics

  • Virtual and digital health
  • Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
  • Value-based healthcare 
  • Precision and stratified medicine
  • Integration of digital technology into existing workflow and procedures 
  • Next-generation immuno, cell, and gene therapies
  • Vaccines
  • Biomarkers, sequencing, and imaging
  • Rare diseases
  • MedTech and medical devices
  • Clinical trials
  • Addressing Social Determinants of Health
  • Treating chronic conditions like obesity and pain
  • Clinician and staff burnout

The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors. 

 

Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.

Empowered Patient Solutions

Jun 25, 2024

Dr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology, discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company initially allowed all AML patients to participate in the clinical study, but later found that specific subtypes, such as those...


Jun 25, 2024

Dr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology, discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company initially allowed all AML patients to participate in the clinical study, but later found that specific subtypes, such as those...


Jun 10, 2024

Nicolas Poirier, CEO of OSE Immunotherapeutics, uses immunology and molecular engineering to develop innovative immunotherapies for oncology, inflammation, autoimmune diseases, and organ transplant.  The same immune cells, lymphocytes and macrophages, are involved in both immuno-oncology and immuno-inflammation, and...


Jun 10, 2024

Nicolas Poirier, CEO of OSE Immunotherapeutics, uses immunology and molecular engineering to develop innovative immunotherapies for oncology, inflammation, autoimmune diseases, and organ transplant.  The same immune cells, lymphocytes and macrophages, are involved in both immuno-oncology and immuno-inflammation, and...


May 6, 2024

John Celebi, the President and Chief Executive Officer of Sensei Biotherapeutics, emphasizes the need to develop better patient selection strategies and next-generation therapeutics for cancer patients. Through their Tumor Microenvironment-Activated Biologics platform (TMAb), Sensei develops conditionally...